Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cantor Fitzgerald
Accenture
Federal Trade Commission
Medtronic
Boehringer Ingelheim

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 6,187,756

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,187,756
Title: Composition and methods for treatment of neurological disorders and neurodegenerative diseases
Abstract:It has been discovered that the stimulation of .beta.-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising .beta.-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by .beta.-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E.sub.2 (PG E.sub.2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of .beta.-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E.sub.2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer\'s Disease.
Inventor(s): Lee; Robert K. K. (Boston, MA), Wurtman; Richard J. (Boston, MA)
Assignee: The Massachusetts Institute of Technology (Cambridge, MA)
Application Number:09/493,228
Patent Claims:see list of patent claims

Details for Patent 6,187,756

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 001 1991-03-05   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 002 1991-03-05   Try a Free Trial The Massachusetts Institute of Technology (Cambridge, MA) 2017-09-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
US Department of Justice
Queensland Health
Mallinckrodt
Medtronic
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.